DrugBiological
Golimumab clinical trials
Also written Simponi and CNTO 148.
- studies test it
- 71
- open now
- 4
- in phase 3
- 31
- first study started
- 2003
Keep track of what changes. Save the golimumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Simponi
- 24
Combined with it in one product
Studies by the year they started
71 studies that test it; most in 2013 (7)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 7 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 6
- Phase 2
- 19
- Phase 3
- 31
- Phase 4
- 15
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 45 · Other 26
Janssen Research & Development, LLC (15) · Centocor, Inc. (15) · Merck Sharp & Dohme LLC (6) · Janssen Pharmaceutical K.K. (3) · Janssen Biotech, Inc. (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · The Leeds Teaching Hospitals NHS Trust (1) · University Ghent (1)
Often tested with
Tested in the same studies.
Infliximab (8) · Methotrexate (8) · Etanercept (5) · Adalimumab (5) · Abatacept (4) · Certolizumab Pegol (4) · Guselkumab (3) · Ustekinumab (3)
Studies
Open first, then newest update. How each study uses golimumab is read from its arms, and is right about nine times in ten.
Testing it · 71
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Golimumab
- Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs PlaceboNot yet recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT07683026Written as Golimumab
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingPhase 3University of NebraskaNCT03414502Written as Golimumab
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingPhase 3University of Erlangen-Nürnberg Medical SchoolNCT04610476Written as Golimumab
- Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyTerminatedPhase 2University of WashingtonNCT05960578Written as Golimumab
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 2Janssen Research & Development, LLCNCT05242484Written as Golimumab
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT03596645Written as Golimumab
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's DiseaseActive, not recruitingPhase 2Janssen Research & Development, LLCNCT05242471Written as Golimumab
- A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic ArthritisCompletedPhase 2Janssen Research & Development, LLCNCT05071664Written as Golimumab
- GOLimumab and Methotrexate Versus Methotrexate in Very Early PsACompletedPhase 3The Leeds Teaching Hospitals NHS TrustNCT04108468Written as Golimumab
- A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate TherapyCompletedPhase 3Janssen Research & Development, LLCNCT02277444Written as Golimumab
- A Study of Golimumab in Participants With Active Ankylosing SpondylitisCompletedPhase 3Janssen Research & Development, LLCNCT02186873Written as Golimumab
- Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut InflammationCompletedPhase 3University GhentNCT03270501Written as Golimumab
- A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic ArthritisCompletedPhase 4Johnson & Johnson Private LimitedNCT03733925Written as Golimumab
- A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)CompletedPhase 4Janssen Scientific Affairs, LLCNCT01804166Written as Golimumab
- A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 DiabetesCompletedPhase 2Janssen Research & Development, LLCNCT02846545Written as Golimumab
- A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 DiabetesCompletedPhase 1Janssen Research & Development, LLCNCT03298542Written as Golimumab
- Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy SubjectsCompletedPhase 1Bio-Thera SolutionsNCT04152759Written as Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
- Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)CompletedPhase 4Merck Sharp & Dohme LLCNCT03253796Written as Golimumab
- A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative ColitisCompletedPhase 1Janssen Research & Development, LLCNCT01900574Written as Golimumab
See all 71 studies that test golimumab →
Given in every arm · 3 — golimumab is usual care beside what is tested
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial SpondyloarthritisTerminatedPhase 3Janssen Research & Development, LLCNCT02437162Written as Golimumab 50 mg
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial SpondyloarthritisTerminatedPhase 3Janssen Research & Development, LLCNCT02438787Written as Golimumab 50 mg
- NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing SpondylitisCompletedPhase 4Charite University, Berlin, GermanyNCT02758782Written as Golimumab
As the comparator · 7 — what is tested is compared with golimumab
- Guselkumab vs Golimumab in PsA TNF Inadequate Responder PatientsRecruitingPhase 3University of PennsylvaniaNCT05669833Written as Golimumab
- A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult ParticipantsCompletedPhase 1Alvotech Swiss AGNCT05632211Written as Simponi
- Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEXCompletedPhase 3Alvotech Swiss AGNCT05842213Written as Simponi (Golimumab)
- A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®CompletedPhase 1Bio-Thera SolutionsNCT05332730Written as Simponi® (EU commercially available product)
- Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGETCompletedPhase 4Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesNCT02425865Written as GOLIMUMAB
- Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGationTerminatedPhase 4Mario Negri Institute for Pharmacological ResearchNCT03100253Written as Golimumab
- Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α BlockersTerminatedPhase 2SanofiNCT01217814Written as Golimumab
Codes
What other systems call golimumab · ClinicalTrials.gg INT005277
- MeSH (NLM) C529000golimumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 91X1KLU43EGOLIMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 819300Confirmed FDA, Wikidata
- Wikidata Q413879golimumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87766GolimumabOne source FDA
- DrugBank DB06674One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C529000 | golimumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 91X1KLU43E | GOLIMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 819300 | — | Confirmed FDA, Wikidata |
| Wikidata | Q413879 | golimumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87766 | Golimumab | One source FDA |
| DrugBank | DB06674 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.